Cited by 440SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Open access

Deng, Wei, Bao, Linlin, Liu, Jiangning, Xiao, Chong, Liu, Jiayi, Xue, Jing, Lv, Qi, Qi, Feifei, Gao, Hong, Yu, Pin, Xu, Yanfeng, Qu, Yajin, Li, Fengdi, Xiang, Zhiguang, Yu, Haisheng, Gong, Shuran, Liu, Mingya, Wang, Guanpeng, Wang, Shunyi, Song, Zhiqi, Liu, Ying, Zhao, Wenjie, Han, Yunlin, Zhao, Linna, Liu, Xing, Wei, Qiang, Qin, Chuan·2020·Science

DOI 10.1126/science.abc5343PMC PMC7402625

Open this paper in CoChat — free account

Abstract

Immunity from reinfection: One of the many open questions about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is whether an individual who has cleared the virus can be infected a second time and get sick. Chandrashekar et al. and Deng et al. generated rhesus macaque models of SARS-CoV-2 infection and tested whether natural SARS-CoV-2 infection could result in immunity to viral rechallenge. They found that animals indeed developed immune responses that protected against a second infection. Although there are differences between SARS-CoV-2 infection in macaques and in humans, these findings have key implications for public health and economic initiatives if validated in human studies. Science , this issue p. 812 , p. 818

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.abc5343

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Positive RT-PCR test results in patients recovered from COVID-19
Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., & Xu, H. (2020) · JAMA · doi:10.1001/jama.2020.2783 · Cited by 1,251
Self-citation
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126
Self-citation
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816
Self-citation
Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Self-citation
Respiratory disease in rhesus macaques inoculated with SARS-CoV-2
Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Williamson, B. N., Feldmann, F., Schwarz, B. H., Meade-White, K. D., Porter, D., Schulz, J. E., van Doremalen, N., Leighton, I. A., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2423-5 · Cited by 696

Flagged first, then by citations

Show all 16 references

Sorted by citations

Items 201–300 of 432

Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment
Ouyang, J., Isnard, S., Lin, J. C.-Y., Fombuena, B., Peng, X., Routy, J., & Chen, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570063 · Cited by 19
Tissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*
Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 19
Animal models for COVID-19 and tuberculosis
Corleis, B., Bastian, M., Hoffmann, D., Beer, M., & Dorhoi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223260 · Cited by 21
Targeting Fc effector function in vaccine design
Richardson, S. I., & Moore, P. L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1907343 · Cited by 20
Animal Hosts and Experimental Models of SARS-CoV-2 Infection
Parolin, C., Virtuoso, S., Giovanetti, M., Angeletti, S., Ciccozzi, M., & Borsetti, A. (2021) · Chemotherapy · doi:10.1159/000515341 · Cited by 20
BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
Ji, R.-R., Qu, Y., Zhu, H., Yang, Y., Vogel, A. B., Şahin, U., Qin, C., & Hui, A. (2021) · Vaccines · doi:10.3390/vaccines9040324 · Cited by 19
Self-citation
Zebrafish models of COVID-19
Tyrkalska, S. D., Candel, S., Pedoto, A., García‐Moreno, D., Alcaraz‐Pérez, F., Sánchez‐Ferrer, Á., Cayuela, M. L., & Mulero, V. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac042 · Cited by 19
SARS-CoV-2-specific T cell memory is long-lasting in the majority of convalsecent COVID-19 individualsPreprint
Li, Z., Liu, J., Deng, H., Yang, X., Wang, H., Feng, X., Zelinskyy, G., Trilling, M., Sutter, K., Lu, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.15.383463 · Cited by 19
Self-citation
Wildlife rehabilitation centers as a potential source of transmission of SARS‐CoV‐2 into native wildlife of Latin America
Chaves, A., Montecino‐Latorre, D., Alcázar, P., & Suzán, G. (2021) · Biotropica · doi:10.1111/btp.12965 · Cited by 18
Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers
Ramos, A., Cardoso, M. J., Ribeiro, L., & Guimarães, J. T. (2022) · Diagnostics · doi:10.3390/diagnostics12010205 · Cited by 18
Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy
Benest, J., Rhodes, S., Quaife, M., Evans, T. G., & White, R. G. (2021) · Vaccines · doi:10.3390/vaccines9020078 · Cited by 18
Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies
Żak, M. M., Stock, A., Stadlbauer, D., Zhang, W., Cummings, K. A., Marsiglia, W. M., Zargarov, A., Amanat, F., Tamayo, M., Cordon‐Cardo, C., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08444 · Cited by 19
An update on host immunity correlates and prospects of re-infection in COVID-19
Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 20
Validating and modeling the impact of high-frequency rapid antigen screening on COVID-19 spread and outcomesPreprint
Nash, B., Badea, A., Reddy, A., Bosch, M., Salcedo, N., Gomez, A. R., Versiani, A. F., da Silva, G. C. D., dos Santos, T., Milhim, B. H. G. D. A., et al. (2020) · medRxiv · doi:10.1101/2020.09.01.20184713 · Cited by 18
RETRACTED: Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19
Mustapha, J. O., Abdullahi, I. N., Ajagbe, O., Emeribe, A. U., Fasogbon, S. A., Onoja, S. O., Ugwu, C. E., Umeozuru, C. M., Ajayi, F. O., Tanko, W. N., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e05951 · Cited by 17
Retracted
Interspecies transmission of SARS CoV-2 with special emphasis on viral mutations and ACE-2 receptor homology roles
Hamdy, M. E., El‐Deeb, A. H., Hagag, N. M., Shahein, M. A., Alaidi, O., & Hussein, H. A. (2023) · International Journal of Veterinary Science and Medicine · doi:10.1080/23144599.2023.2222981 · Cited by 17
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
Boekel, L., Hooijberg, F., Vogelzang, E., Besten, Y., Leeuw, M., Atiqi, S., van Vollenhoven, R. F., Wijbrandts, C., Gerritsen, M., Krieckaert, C., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2021-002035 · Cited by 16
SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunctionPreprint
Millette, K., Cuala, J., Wang, P., Marks, C., Woo, V., Hayun, M., Kang, H., Martı́n, M. G., Dhawan, S., Chao, L. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-592374/v1 · Cited by 17
SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract
Hansen, F., Meade-White, K. D., Clancy, C. S., Rosenke, R., Okumura, A., Hawman, D. W., Feldmann, F., Kaza, B., Jarvis, M. A., Rosenke, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110515 · Cited by 16
Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
Phelan, T., Dunne, J., Conlon, N. P., Cheallaigh, C. N., Abbott, W. M., Faba-Rodriguez, R., Amanat, F., Krammer, F., Little, M. A., Hughes, G., et al. (2021) · Viruses · doi:10.3390/v13071371 · Cited by 16
High Rate of Mutational Events in SARS-CoV-2 Genomes across Brazilian Geographical Regions, February 2020 to June 2021
de Souza, U. J. B., dos Santos, R. N., Campos, F. S., Lourenço, K. L., da Fonseca, F. G., Spilki, F. R., & Corona-ômica.BR/MCTI Network (2021) · Viruses · doi:10.3390/v13091806 · Cited by 16
Structural Bases of Zoonotic and Zooanthroponotic Transmission of SARS-CoV-2
Clayton, E., Ackerley, J., Aelmans, M., Ali, N. A. M., Ashcroft, Z., Ashton, C., Barker, R., Budryte, V., Burrows, C., Cai, S., et al. (2022) · Viruses · doi:10.3390/v14020418 · Cited by 16
Differential transcriptomic landscapes of multiple organs from SARS-CoV-2 early infected rhesus macaques
Gao, C., Li, M., Deng, W., Ma, C., Chen, Y., Sun, Y., Du, T., Liu, Q.-L., Li, W., Zhang, B., et al. (2022) · Protein & Cell · doi:10.1007/s13238-022-00915-5 · Cited by 16
Self-citation
Second Episode of COVID-19 in Health Professionals: Report of Two Cases
de Brito, C. A. A., Lima, P. M. A., de Brito, M. C. M., & de Oliveira, D. B. (2020) · International Medical Case Reports Journal · doi:10.2147/imcrj.s277882 · Cited by 15
Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy
Shimizu, Y. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i23.5835 · Cited by 16
Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies
Garritsen, A., Scholzen, A., van den Nieuwenhof, D. W. A., Smits, A. P. F., Datema, E. S., van Galen, L. S., & Kouwijzer, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1893378 · Cited by 15
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination
Jalkanen, P., Kolehmainen, P., Haveri, A., Huttunen, M., Laine, L., Österlund, P., Tähtinen, P. A., Ivaska, L., Maljanen, S., Reinholm, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02252-21 · Cited by 15
Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2Preprint
Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H. R., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3739808 · Cited by 15
Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam
Mai, H. K., Trieu, N. B., Long, T. H., Thanh, H. T., Lượng, N. Đ., Huy, L. X., Nguyet, L. A., Man, D. N. H., Anderson, D. E., Thanh, T. T., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2702.204226 · Cited by 15
Immunity after COVID-19: Protection or sensitization?
Danchin, A., & Turinici, G. (2020) · Mathematical Biosciences · doi:10.1016/j.mbs.2020.108499 · Cited by 14
Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31
Levi‐Schaffer, F., & de Marco, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15359 · Cited by 14
Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination
Hedges, J. F., Thompson, M. A., Snyder, D. T., Robison, A., Taylor, M. P., & Jutila, M. A. (2021) · Vaccines · doi:10.3390/vaccines9060587 · Cited by 14
Persistence of humoral response upon SARS‐CoV‐2 infection
Knies, A., Ladage, D., Braun, R. J., Kimpel, J., & Schneider, M. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2272 · Cited by 17
Characteristics of animal models for COVID‐19
Qi, F., & Qin, C. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12278 · Cited by 14
Self-citation
Endothelial cell, myeloid, and adaptive immune responses in SARS‐CoV‐2 infection
Degauque, N., Haziot, A., Brouard, S., & Mooney, N. (2021) · The FASEB Journal · doi:10.1096/fj.202100024r · Cited by 14
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
Li, C., Yu, D., Wu, X., Liang, H., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L., et al. (2021) · doi:10.1101/2021.04.05.437224 · Cited by 73
6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort
Deisenhammer, F., Borena, W., Bauer, A., Kimpel, J., Rudzki, D., Schanda, K., Egeter, J., Hüfner, K., Sperner‐Unterweger, B., & Reindl, M. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01795-7 · Cited by 13
Advancements in organs-on-chips technology for viral disease and anti-viral research
Li, J., Bai, H., Wang, Z., Beibei, X., Olson, K. N. P., Liu, C., Su, Y., Hao, J., Shen, J., Xi, X., et al. (2023) · Organs-on-a-Chip · doi:10.1016/j.ooc.2023.100030 · Cited by 13
Self-citation
Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study
Wang, H., Wen, T., Zhu, W., Li, K., Gong, X., & Li, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100905 · Cited by 13
The SARS-CoV-2 antibody-dependent enhancement façade
Coish, J. M., MacNeil, L. A., & MacNeil, A. J. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105464 · Cited by 13
Further information on possible animal sources for human COVID‐19
Opriessnig, T., & Huang, Y. (2020) · Xenotransplantation · doi:10.1111/xen.12651 · Cited by 15
Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model
Day, J., Park, S., Ranard, B. L., Singh, H., Chow, C. C., & Yoram Vodovotz, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754127 · Cited by 13
Insights Into the Changing Landscape of Coronavirus Disease 2019
Escobedo, R. A., Kaushal, D., & Singh, D. K. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.761521 · Cited by 14
T cell responses to SARS-CoV-2 in humans and animals
Mattoo, S.-U.-S., & Myoung, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1624-z · Cited by 13
Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut
Papasavas, P. K., Olugbile, S. O., Wu, U., Robinson, K. J., Roberts, A. L., O’Sullivan, D. M., McLaughlin, T., Mather, J., Steinberg, A. C., Orlando, R., et al. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.04.021 · Cited by 13
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
Psichοgiou, M., Karabinis, A., Poulakou, G., Antoniadou, A., Kotanidou, Α., Degiannis, D., Pavlopoulou, I. D., Chaidaroglou, A. S., Roussos, S., Mastrogianni, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9091017 · Cited by 13
Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges
Masterson, C. H., Ceccato, A., Artigas, A., dos Santos, C. C., Rocco, P. R. M., Enes, S. R., Weiss, D. J., McAuley, D. F., Matthay, M. A., English, K., et al. (2021) · Intensive Care Medicine Experimental · doi:10.1186/s40635-021-00424-5 · Cited by 12
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination
Graninger, M., Camp, J. V., Aberle, S. W., Traugott, M. T., Hoepler, W., Puchhammer‐Stöckl, E., Weseslindtner, L., Zoufaly, A., Aberle, J. H., & Stiasny, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888794 · Cited by 12
Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms
Carreño, J. M., Mendu, D. R., Simon, V. R., Shariff, M. A., Singh, G., Menon, V. P., & Krammer, F. (2021) · iScience · doi:10.1016/j.isci.2021.102937 · Cited by 12
Blood Analysis of LaboratoryMacaca mulattaUsed for Neuroscience Research: Investigation of Long-Term and Cumulative Effects of Implants, Fluid Control, and Laboratory Procedures
Wegener, D., Oh, D. Q. P., Lukaß, H., Böer, M., & Kreiter, A. K. (2021) · eNeuro · doi:10.1523/eneuro.0284-21.2021 · Cited by 12
Anti-SARS-CoV-2 IgG responses are powerful predicting signatures for the outcome of COVID-19 patients
Lei, Q., Yu, C., Li, Y., Hou, H., Xu, Z., Yao, Z., Zhang, Y., Lai, D., Ndzouboukou, J. B., Zhang, B., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.014 · Cited by 12
Self-citation
Should we concern about reinfection in COVID-19?
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., & Villamil‐Gómez, W. E. (2020) · Infectio · doi:10.22354/in.v25i2.922 · Cited by 12
Current mutatome of SARS-CoV-2 in Turkey reveals mutations of interest
Eskier, D., AKALP, E., Dalan, Ö., Karakülah, G., & Oktay, Y. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2008-56 · Cited by 11
Assay dependence of long-term kinetics of SARS-CoV-2 antibodies
Schallier, A., Baets, S. D., Bruyne, D. D., Dauwe, K., Herpol, M., & Couck, P. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115403 · Cited by 11
COVID-19 and SARS-CoV-2: Everything we know so far – A comprehensive review
Naz, S., Zahoor, M., Sahibzada, M. U. K., Ullah, R., & Alqahtani, A. S. (2021) · Open Chemistry · doi:10.1515/chem-2021-0049 · Cited by 14
Interlaboratory comparison of SARS-CoV2 molecular detection assays in use by U.S. veterinary diagnostic laboratories
Deng, K., Uhlig, S., Ip, H. S., Killian, M. L., Goodman, L. B., Nemser, S. M., Ulaszek, J., Pickens, S. R., Newkirk, R., Kmet, M., et al. (2021) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/10406387211029913 · Cited by 11
COVID-19: Immune response
Al-Hamamy, H. R. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00076 · Cited by 11
Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization
Harvala, H., Nguyen, D. V., Peter Simmonds, K., Lamikanra, A., Tsang, H. P., Otter, A. D., Maes, P., Webster, M., Clarkson, A., Kaloyirou, F., et al. (2022) · Transfusion · doi:10.1111/trf.16934 · Cited by 12
Generation and Characterization of a SARS-CoV-2-Susceptible Mouse Model Using Adeno-Associated Virus (AAV6.2FF)-Mediated Respiratory Delivery of the Human ACE2 Gene
Tailor, N., Warner, B. M., Griffin, B. D., Tierney, K. J., Moffat, E., Frost, K. L., Vendramelli, R., Leung, A., Willman, M., Thomas, S. P., et al. (2022) · Viruses · doi:10.3390/v15010085 · Cited by 11
Intrinsic factors behind long COVID: III. Persistence of SARS‐CoV‐2 and its components
El‐Baky, N. A., Amara, A. A. A. F., Uversky, V. N., & Redwan, E. M. M. M. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30514 · Cited by 11
SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity
Müllbacher, A., Pardo, J., & Furuya, Y. (2020) · Pathogens · doi:10.3390/pathogens9110928 · Cited by 11
Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage
Kim, G., Kim, D. H., Oh, H., Bae, S., Kwon, J., Kim, M., Lee, E., Hwang, E.-H., Jung, H., Koo, B., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab535 · Cited by 11
Exploring Influenza A Virus-Induced Lung Injury and Immune Response Based on Humanized Lung-on-Chip
Gu, S., Pan, P., Wang, J., Shi, Y., Shi, F., Zhang, Y., Guan, W., Cao, Y., Qin, H., Wang, Q., et al. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335177.55 · Cited by 10
COVID‐19 reinfection in a healthcare worker after exposure with high dose of virus: A case report
Ahmadian, S., Fathizadeh, H., Khiabani, S. S., Asgharzadeh, M., & Kafil, H. S. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4257 · Cited by 10
Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China
Huang, Z., Fu, Z., & Wang, J. (2022) · Engineering · doi:10.1016/j.eng.2022.01.001 · Cited by 10
B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
Bai, Y., He, Q., Yang, J., Lu, S.-Y., Mao, Q.-Y., Gao, F., Bian, L.-L., Zhang, J., An, C., Liu, J., et al. (2022) · Microbiology spectrum · doi:10.1128/spectrum.02263-22 · Cited by 10
Self-citation
Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2
Francis, M. E., Jansen, E. B., Yourkowski, A., Selim, A., Swan, C. L., MacPhee, B. K., Thivierge, B. M., Buchanan, R. M., Lavender, K. J., Darbellay, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41761-1 · Cited by 11
Using in vivo animal models for studying SARS-CoV-2
da Costa, C. B. P., Cruz, A. C. D. M., Penha, J. C. Q., Castro, H. C., da Cunha, L. E. R., Ratcliffe, N. A., Cisne, R., & Martins, F. J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1995352 · Cited by 11
Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity
Thieme, C. J., Abou‐El‐Enein, M., Fritsche, E., Anft, M., Paniskaki, K., Skrzypczyk, S., Doevelaar, A., Elsallab, M., Brindle, N. R., Blazquez‐Navarro, A., et al. (2021) · Allergy · doi:10.1111/all.14827 · Cited by 10
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
Sulbarán, G., Maisonnasse, P., Amen, A., Effantin, G., Guilligay, D., Dereuddre‐Bosquet, N., Burger, J. A., Poniman, M., Grobben, M., Buisson, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100528 · Cited by 11
A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and controls for pre-existing seasonal human coronavirus antibody cross-reactivityPreprint
Laing, E. D., Sterling, S. L., Richard, S. A., Phogat, S., Samuels, E. C., Epsi, N. J., Yan, L., Moreno, N., Coles, C., Mehalko, J. L., et al. (2020) · medRxiv · doi:10.1101/2020.10.14.20207050 · Cited by 10
A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and antibody cross reactionsPreprint
Laing, E. D., Sterling, S. L., Richard, S. A., Epsi, N. J., Phogat, S., Samuels, E. C., Yan, L., Moreno, N., Coles, C., Drew, M. R., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-105768/v1 · Cited by 10
Dynamics of infection-elicited SARS-CoV-2 antibodies in children over timePreprint
Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J. A., Wolf, C. R., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., et al. (2022) · medRxiv · doi:10.1101/2022.01.14.22269235 · Cited by 11
SARS-Cov-2 spike induces intestinal barrier dysfunction through the interaction between CEACAM5 and Galectin-9
Luo, Y., Zhang, Z., Ren, J., Dou, C., Wen, J., Yang, Y., Li, X., Yan, Z., & Han, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1303356 · Cited by 10
Self-citation
Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques
Willcox, A. C., Sung, K., Garrett, M. E., Galloway, J., O’Connor, M. A., Erasmus, J. H., Logue, J. K., Hawman, D. W., Chu, H. Y., Hasenkrug, K. J., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010155 · Cited by 9
Clinical severity according to the primary infection variant in patients with suspected SARS-CoV-2 reinfection in Korea
Hwang, M.-J., Hwang, I., Park, C., Park, H., Son, T., & Kim, J. (2022) · Epidemiology and Health · doi:10.4178/epih.e2023007 · Cited by 9
Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice
Patel, R. S., & Agrawal, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1178523 · Cited by 9
Long-term sero-positivity for IgG, sequelae of respiratory symptoms, and abundance of malformed sperms in a patient recovered from severe COVID-19
Zhu, M.-C., Chen, D., Zhu, Y., Xiong, X.-S., Ding, Y., Guo, F., Zhu, M.-G., & Zhou, J. (2021) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-021-04178-6 · Cited by 7
Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans
Yang, S.-Y., Jerome, K. R., Greninger, A. L., Schiffer, J. T., & Goyal, A. (2021) · Viruses · doi:10.3390/v13030516 · Cited by 9
Understanding COVID-19: From Dysregulated Immunity to Vaccination Status Quo
Escobedo, R. A., Singh, D. K., & Kaushal, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765349 · Cited by 10
Potential intestinal infection and faecal‐oral transmission of human coronaviruses
Ning, T., Liu, S., Xu, J., Yang, Y., Zhang, N., Xie, S.-A., Min, L., Zhang, S., Zhu, S., & Wang, Y. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2363 · Cited by 9
COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10
A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19
Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00533-4 · Cited by 8
Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure
Sánchez‐Montalvá, A., Fernández‐Naval, C., Antón, A., Durà-Miralles, X., Vimes, A., Silgado, A., Velásquez-Orozco, F., Pereiro, J. E., Salvador, F., Pumarola, T., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091968 · Cited by 8
Study of Gold Nanoparticles Conjugated with SARS-CoV-2 S1 Spike Protein Fragments
Jelen, Ž., Kovač, J., & Rudolf, R. (2023) · Nanomaterials · doi:10.3390/nano13152160 · Cited by 8
Animal Models of Non-Respiratory, Post-Acute Sequelae of COVID-19
Vanderheiden, A., & Diamond, M. (2025) · Viruses · doi:10.3390/v17010098 · Cited by 9
Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters
Zhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.722178 · Cited by 8
Self-citation
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
Current state-of-the-art and potential future therapeutic drugs against COVID-19
Sha, A., Liu, Y., & Hao, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1238027 · Cited by 8
Self-citation
Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters
Diego, J. G.-B., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. S. E., Pache, L., Chang, M. W., Warang, P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011805 · Cited by 8
Respiratory Tract Explant Infection Dynamics of Influenza A Virus in California Sea Lions, Northern Elephant Seals, and Rhesus Macaques
Liu, H.-W., Plancarte, M., Ball, E., Weiss, C. M., Gonzales-Viera, O., Holcomb, K. M., Ma, Z.-M., Allen, A. M., Reader, J., Duignan, P., et al. (2020) · bioRxiv · doi:10.1128/jvi.00403-21 · Cited by 7
SARS‐CoV‐2 and wastewater: What does it mean for non‐human primates?
Mathavarajah, S., Melin, A. D., & Dellaire, G. (2021) · American Journal of Primatology · doi:10.1002/ajp.23340 · Cited by 8
Optimising social mixing strategies to mitigate the impact of COVID-19 in six European countries: a mathematical modelling studyPreprint
Ragonnet, R. R., Briffoteaux, G., Williams, B. M., Savulescu, J., Segal, M., Abayawardana, M., Eggo, R. M., Tuyttens, D., Melab, N., Marais, B. J., et al. (2020) · medRxiv · doi:10.1101/2020.08.25.20182162 · Cited by 8
A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.Preprint
Baisa, G. A., Rancour, D. M., Mansfield, K. G., Burns, M. A., Martin, L., Cunha, D., Fischer, J., Muecksch, F., Hatziioannou, T., Bieniasz, P. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.21203/rs.3.rs-137857/v1 · Cited by 8
Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2
Kršák, M., Harry, B. L., Palmer, B. E., & Franco‐Paredes, C. (2021) · Viral Immunology · doi:10.1089/vim.2021.0054 · Cited by 8
Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates
Stepanova, E., Isakova–Sivak, I., Matyushenko, V., Mezhenskaya, D. А., Kudryavtsev, I., Kostromitina, A. D., Chistyakova, A. K., Rak, A. Y., Bazhenova, E. A., Prokopenko, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12101099 · Cited by 7
Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers
Lim, S., Lee, Y., Kim, D. W., Park, W. S., Yoon, J. H., & Lee, J. Y. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0009 · Cited by 7
Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China
Yan, L., Zhao, Z., Wang, Z., Xiao, X., Liu, P., Zhang, W., Gu, X., Li, B., Yu, L., & Yu, X. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2104714 · Cited by 7
Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern
García‐Pérez, J., Bermejo, M., Ramírez‐García, A., Tarazona, E. D. L. T., Cascajero, A., de la Osa, M. C., Jiménez, P., Gómez, M. A., Calonge, E., Sancho‐López, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28679 · Cited by 7
Role of serology tests in COVID-19 non-hospitalized patients: A cross-sectional study
Ashtıani, M. T. H., Rad, P. S., Asnaashari, K., Shah-Hosseini, A., Berenji, F., & Mamishi, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266923 · Cited by 7

Authors: Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., Xu, Y., Qu, Y., Li, F., Xiang, Z., Yu, H., Gong, S., Liu, M., Wang, G., Wang, S., Song, Z., Liu, Y., Zhao, W., Han, Y., Zhao, L., Liu, X., Wei, Q., & Qin, C.
Affiliations: Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Capital Medical University (CN)
Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
Corresponding author: Deng, Wei
Bao, Linlin
Liu, Jiangning
Xiao, Chong
Liu, Jiayi
Xue, Jing
Lv, Qi
Qin, Chuan
ORCID: Deng, Wei
Bao, Linlin
Liu, Jiangning
Xiao, Chong
Liu, Jiayi
Xue, Jing
Lv, Qi
Qi, Feifei
Gao, Hong
Yu, Pin
Xu, Yanfeng
Qu, Yajin
Xiang, Zhiguang
Yu, Haisheng
Gong, Shuran
Liu, Mingya
Wang, Guanpeng
Wang, Shunyi
Song, Zhiqi
Liu, Ying
Zhao, Wenjie
Han, Yunlin
Zhao, Linna
Liu, Xing
Wei, Qiang
Qin, Chuan
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2020-08-14
Volume: 369
Issue: 6505
Pages: 818-823
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.abc5343
PMC: PMC7402625
OpenAlex: W3038698073
Cited by: 440
References: 16
Citations by year: 2026: 6 · 2025: 11 · 2024: 18 · 2023: 41 · 2022: 84 · 2021: 176 · 2020: 104
FWCI: 13.33
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Science (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: National key research and development project of China (2016YFD0500304)
National Mega projects of China for Major Infectious Diseases (2017ZX10304402)
CAMS Initiative for Innovative Medicine of China (2016-I2M-2-006)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, COVID-19 pandemic, reinfection, rhesus monkeys, primary infection, drug rechallenge, neutralizing antibodies, humoral immunity, cell-mediated immunity, interstitial lung disease, viral dissemination, convalescence
MeSH terms: Betacoronavirus, Host Microbial Interactions, COVID-19, SARS-CoV-2, Animals, Antibodies, Viral, Anal Canal, Disease Models, Animal, Immunity, Cellular, Lung, Macaca mulatta, Nasopharynx, Pneumonia, Viral, Recurrence, Virus Replication, B-Lymphocyte Subsets, T-Lymphocyte Subsets, Lung Diseases, Interstitial, Coronavirus Infections, Viral Load, Immunity, Humoral, Antibodies, Neutralizing, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks